-
Drug interactions are almost impossible to avoid in the care of HIV patients, said David Back, University of Liverpool. The risk for polypharmacy and thus for interactions increases with age due to increased comorbidities and physiological changes.
-
Obesity has many consequences for the health of those affected. John R. Koethe, Vanderbilt University Medical Center, Nashville, TN, USA, presented the current state of research at the CROI 2019.
-
With only a few studies available, the current WHO recommendations are mainly based on observations. Jennifer Furin, Harvard Medical School, USA, presented current developments in MDR-TB treatments.
-
Latent HI viruses are the first target of the so-called shock-and-kill strategy. As part of this strategy, latency is eliminated by Latency Reversing Agents (LRAs).
-
HIV-positive men who have sex with men (MSM) are particularly affected, but HIV-negative men are also becoming increasingly infected. Although the therapy is expensive, it is highly effective, preventative and overall cost-efficient when used early.
-
Jeffrey Cohen, National Institute of Allergy and Infectious Diseases, USA, reported on the current developments pertaining to the development of vaccine options against the Epstein-Barr virus.
-
Kaposi's sarcoma-associated herpesvirus (KSHV) can modulate the innate immune response by producing various proteins. Damania Blossom, from the University of North Carolina, Chapel Hill, USA, presented experimental data at the CROI 2019.
-
Drug therapy for pregnant women is a balancing act between maternal treatment and the possible harm to the unborn child. Lynne Meryl Mofenson (Elizabeth Glaser Pediatric AIDS Foundation, USA) presented the most recent research on antiretroviral agents treatments for pregnant women.
-
Mark R. Pakianathan, from the School of Hygiene and Tropical Medicine, St. George's University of London, addressed the role of Chemsex in the spread of sexually transmitted infections (STI), hepatitis C and especially HIV.
-
The Musculoskeletal Working Group on Hemophilia brought together experts to develop guidelines about "Synovitis in Hemophilia". The determination of the trough level, i.e. the factor level immediately before the next injection, and patient adherence are relevant for prophylaxis.
-
Results from the randomized prophylaxis phase III PROPEL study were presented. The study shows zero rates of total bleeding and spontaneous joint bleeding that have not been reported by people with hemophilia A before.
-
At the 63rd Annual Meeting of the Society for Thrombosis and Haemostasis Research, Florian Langer, Hamburg, and Martin Grünewald discussed the pros and cons of using DOACs in tumor-associated VTE.
-
Some hemophilia patients develop antibodies against the coagulation factors administered during therapy. To remove such so-called inhibitors, immunotolerance therapy has been used. This, however, is expensive, painful and often has limited effectiveness.
-
Anticoagulation is important in prophylaxis for atrial fibrillation patients. Although warfarin still belongs in the armamentarium, current studies show that the novel oral anticoagulants (NOAC) are partially superior to vitamin K antagonists.
-
The Professional Association of German Hemostaseologists (BDDH) gathered speakers from the health and insurance sectors to present their views on the one-year-treatment contract approach.
-
What to do if the suspicion of violence during the examination is confirmed
-
A team of researchers from the Universities of California and New York conducted an economic feasibility study to analyze the cost-effectiveness model of cannabis adjuvant drug therapy for chronic peripheral neuropathy.
-
CAR-T cells have been a recent success story in the treatment of various leukemias and lymphomas. But their fight against solid tumor diseases has failed as the T cells cannot enter the macrophages mantle around a tumor site. However, this could now change.
-
In the past two years, there have been repeated measles outbreaks throughout Europe. This is due to insufficient vaccination coverage. Is Europe now saying goodbye to measles eradication or can this achievement still be saved?
-
Radioligand therapy is still a new experimental form of treatment in urooncology. But now the first successes with PSMA-Lutetium-177 have been achieved in prostate cancer. Time to take a closer look at the method.
